Artgen Biotech reported for 9 months of 2023

Artgen Biotech's EBITDA for 9 months of 2023 amounted to ₽209.72 million, up 67.7% from ₽125.02 million in the previous year. Revenue increased 17.9% to ₽963.98 million against ₽817.89 million a year earlier.